Genetics of clozapine use because of schizophrenia, schizo-affective disorder, schizophreniform disorder
Conditions
Interventions
None
Sponsors
Dr. J. Luykx
Eligibility
Inclusion criteria
Inclusion criteria: -he/she currently uses CLZ -he/she has received a diagnosis of schizophrenia, schizophreniform disorder, schizoaffective disorder or psychosis not otherwise specified -his/her age must be ≥18 years old -he/she must be able to speak and read the Dutch language -he/she must be mentally competent and have decisional capacity with regard to a decision to participate in the current study
Exclusion criteria
Exclusion criteria: - admission to a psychiatric unit involuntarily in the context of an ‘inbewaringstelling’ (IBS) - a history of Parkinson’s disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| First, in a discovery cohort a case-control genome-wide association study (GWAS) will be performed on 2000 CLZ using subjects (cases) and >30,000 already available SCZ patients (controls, drawn from the most recent Psychiatric Genomics Consortium analysis, . We hereby aim to reveal potential differences in the genetic architecture between the severe CLZ-SCZ phenotype and the broad SCZ phenotype. | — |
Secondary
| Measure | Time frame |
|---|---|
| Second, a replication cohort of the same size as the discovery cohort (N=2,000 CLZ using subjects and the same number of controls) will be used to replicate any positive associations for each of the two GWAS analyses. Should funding allow and if replication cohorts are available elsewhere and possibly for the purpose of participation in large-scale consortia, GWAS and NGS may be performed on >2,000 CLZ users, e.g. the entire study population. In addition, we use the data with our other protocol (NTR 5257) to create a prediction model for clozapine response and side effects. | — |
Contacts
Public ContactMarte van der Horst
UMCU A01.126
Outcome results
None listed